As India’s obesity rate surges, the pharmaceutical industry is preparing for a game-changing shift in the country’s weight-loss market. By 2025, globally renowned injectable treatments like Ozempic, Zepbound, and Mounjaro are poised to make their debut, offering promising solutions for those battling obesity. However, the road ahead is fraught with challenges ranging from regulatory hurdles to the high cost of treatment.
The Weight Loss Crisis in India
Over the past decade, India has seen a dramatic rise in obesity, with the percentage of obese individuals climbing from 25% in 2013 to a staggering 40% in 2023. This alarming trend signals a growing need for effective and accessible weight-management solutions. Traditionally, weight loss in India has been associated with fad diets, fitness regimes, and Ayurvedic treatments. However, the upcoming arrival of scientifically backed injectable drugs promises to revolutionize the market.
What Are Ozempic, Zepbound, and Mounjaro?
These drugs, already making headlines in Western countries, target the root causes of weight gain and obesity-related health conditions, such as diabetes and hypertension.
Ozempic, a popular injectable containing semaglutide, works by mimicking the GLP-1 hormone, which regulates blood sugar, enhances insulin secretion, and promotes satiety. Widely endorsed by public figures like Elon Musk, Ozempic has gained traction even in India, where many import it from abroad.
Zepbound and Mounjaro, both containing tirzepatide, function as dual agonists, targeting the GLP-1 and GIP receptors. Zepbound is approved for weight management in adults with obesity, while Mounjaro is branded for the treatment of Type 2 diabetes, although it also facilitates weight loss. Experts like Dr. Samrat Shah of Apollo Spectra Hospital, Pune, note that these drugs provide more comprehensive solutions, targeting both appetite and fat storage.
Side Effects and Concerns
Despite their potential, these injectables are not without risks. Side effects have sparked concerns among healthcare professionals, including warnings about thyroid tumours observed in animal studies. Additionally, some patients have reported muscle loss, commonly referred to as “Ozempic face” or “Ozempic body,” a side effect linked to rapid weight loss.
Dr. Tushar Tayal, a consultant at CK Birla Hospital in Gurugram, emphasizes the importance of addressing these concerns to ensure patient safety. “The risk of thyroid-related side effects is significant, and patients must be informed of these risks,” he says. Moreover, the tendency for weight to return after discontinuing treatment is another challenge faced by those using these drugs.
The financial aspect is another deterrent. With a price tag of Rs 9,000-10,000 per injection, these treatments remain inaccessible to the majority of India’s population, raising concerns about affordability and sustainability in the long term.
Potential Impact on India’s Weight Loss Landscape
Despite these challenges, experts predict that the introduction of Ozempic, Zepbound, and Mounjaro could disrupt India’s weight-loss market. With obesity rates climbing, there is a substantial demand for effective solutions. Rahul Kamra, a weight-loss expert and founder of Ketorets, highlights the growing appeal of scientifically validated treatments. “With diabetes and obesity on the rise, these injectables offer a clinically proven option that could appeal to many,” Kamra explains.
As the launch of these drugs is expected by 2025-2026, the weight-loss market—traditionally dominated by fitness plans and natural remedies—could shift dramatically. According to Dr. Tayal, the rise of injectables might challenge the dominance of traditional weight-loss methods, including diets and herbal products, while also altering the way Indians approach health and wellness.
Barriers to Market Penetration
Before these drugs can reach the Indian market, however, several obstacles remain. The regulatory process, overseen by the Central Drugs Standard Control Organisation (CDSCO), can take anywhere from 12 to 18 months, with the requirement for extensive clinical trials to ensure the drug’s safety and efficacy for Indian consumers.
Price is another key factor that could hinder widespread adoption. At current rates, the cost of these injections remains prohibitive for most Indians. Dr. Tayal stresses the need for companies to explore pricing strategies that make these treatments more accessible to a broader population.
Moreover, as Dr. Vaishali Naik, an endocrinologist at Lilavati Hospital in Mumbai, points out, there is a cultural hesitancy toward using pharmaceutical interventions for weight loss. “Indians tend to favor natural remedies and holistic approaches, and convincing the public to trust injectable medications might be an uphill task,” she says.
Education and Acceptance: Key to Success
Once these drugs are approved and launched, experts agree that widespread education will be essential to their success. Both healthcare professionals and patients will need to be informed about the benefits, risks, and proper use of these medications. Given the popularity of Ayurvedic treatments and the skepticism surrounding pharmaceutical solutions, the acceptance of these injectables could take time.
However, if these hurdles can be overcome, Ozempic, Zepbound, and Mounjaro have the potential to reshape India’s weight-loss market and provide millions of people with a more effective means of managing obesity and related health conditions.
As India faces a growing obesity epidemic, the arrival of these cutting-edge weight loss drugs marks a turning point in the country’s healthcare landscape. While the road to widespread adoption is fraught with challenges, experts agree that the potential benefits—if made accessible and affordable—could transform the lives of many struggling with obesity.
Related topic：
